Journal: bioRxiv

Article Title: A designed overlapping variant immunogen pool elicits broad sarbecovirus neutralization

doi: 10.64898/2026.06.03.729821

Figure Lengend Snippet: (A) Design and execution of an immunogen efficacy experiment to test the longevity of protection against SARS-CoV-2 variants that might emerge after immunization. Mice received two doses of immunogen, and were challenged one year later with whatever SARS-CoV-2 variant was prevalent one year after the design of the immunogen. (B-F) Neutralizing titers (NT 50 ) over time (up to 1 year) against SARS-CoV-2 Wu , SARS-CoV-2 XBB, SARS-CoV-2 KP2/3 pseudotypes in mouse sera after immunization with two doses of the indicated immunogens. Graph title indicates immunogen, each line represents 1 mouse, n = 6 mice per group. Dotted line indicates the lowest sera dilution tested (1:50). (G) SARS-CoV-2 KP.3.1 lung viral loads on day 3 after infection of K18-hACE2 mice, immunized one year previously with two doses of indicated immunogen. Each symbol represents mean of measurements from the left lung and right lung of each mouse, black line = group median. Dotted line indicates limit of detection. (H) Lung viral loads (rVSV/SARS-1 RNA copies per μg total RNA) on day 3 after infection of K18-hACE2 IFNAR(-/-) mice, immunized 12 weeks prior with two doses of indicated immunogen. Each symbol represents one mouse lung, each line represents group median. Dotted line indicates limit of detection.

Article Snippet: All mouse studies were performed in compliance with the Rockefeller University Institutional Animal Care and Use Committee (IACUC) according to animal protocol 24016-H. For analysis of neutralizing antibody responses, ten-week old C57BL/6 (JAX Strain #000664) and K18-hACE2 transgenic mice expressing the human ACE [B6.

Techniques: Variant Assay, Infection

Journal: bioRxiv

Article Title: A designed overlapping variant immunogen pool elicits broad sarbecovirus neutralization

doi: 10.64898/2026.06.03.729821

Figure Lengend Snippet: (A,B) Comparison of neutralizing titers (NT 50 ) against SARS-CoV-2 variant pseudotypes in mouse sera 12 and 51 weeks post-immunization with two doses of indicated immunogen. Each symbol represents 1 mouse, lines = group mean, n = 5-6 mice per group. Dotted line indicates the lowest sera dilution tested (1:50). (C) Validation of SARS-CoV-2 challenge virus stocks, KP.3 and KP.3.1. Lung viral loads (SARS-CoV-2 RNA copies per μg total RNA) on day 3 after infection of K18-hACE2 mice. Each symbol represents 1 mouse, lines = group geometric mean, n=5 mice per group (D) Lung viral loads (rVSV/SARS-1 RNA copies per μg total lung RNA) on each of the indicated hours after infection of K18-hACE2 IFNAR(-/-) mice. Each symbol represents 1 mouse, dotted line=limit of detection.

Article Snippet: All mouse studies were performed in compliance with the Rockefeller University Institutional Animal Care and Use Committee (IACUC) according to animal protocol 24016-H. For analysis of neutralizing antibody responses, ten-week old C57BL/6 (JAX Strain #000664) and K18-hACE2 transgenic mice expressing the human ACE [B6.

Techniques: Comparison, Variant Assay, Biomarker Discovery, Virus, Infection

Journal: PLOS Pathogens

Article Title: Collectin-11, a complement pattern recognition molecule, mediates pulmonary SARS-CoV-2 neutralization and protection

doi: 10.1371/journal.ppat.1014216

Figure Lengend Snippet: (A-C) Neutralization of infectious SARS-CoV-2 following incubation with two-fold dilutions of rCL-11 (black) in A549-hACE-2 cells (starting at 40 µg/ml) (A) , Calu-3 cells (starting at 20 µg/ml) (B) , and Huh7.5 cells (starting at 20 µg/ml) (C) using the conventional experimental setup. The mAb clone 61 was used as a neutralization control (orange) and rCL-11 buffer (gray) in corresponding dilutions was used to monitor buffer-mediated effects on the cells. The percentage of protected cells was determined from the number of SARS-CoV-2 infected cells in experimental wells compared to the number of infected cells in virus-only control wells after anti-S protein immunostaining. Data are shown as means ± SD of four (A549-hACE-2 and Calu-3 cells) or six (Huh7.5 cells) replicates.

Article Snippet: The human lung adenocarcinoma A549-hACE-2 cell line (InvivoGen, San Diego, California, USA) (A549 cells expressing human ACE-2) was maintained as described previously [ ].

Techniques: Neutralization, Incubation, Control, Infection, Virus, Immunostaining